Preview

Современная ревматология

Расширенный поиск

Показатели рентгенологического прогрессирования и выраженности воспаления по результатам магнитно-резонансной томографии у больных ревматоидным артритом, анкилозирующим спондилитом и псориатическим артритом под влиянием терапии голимумабом

https://doi.org/10.14412/1996-7012-2013-2387

Полный текст:

Аннотация

В статье представлены данные о прогрессировании рентгенологических и магнитно-резонансных изменений в суставах кистей и стоп у больных ревматоидным артритом и псориатической артропатией и в осевом скелете у больных анкилозирующим спондилитом при использовании голимумаба (ГЛМ). Показано, что терапия ГЛМ сдерживала прогрессирование структурных изменений в периферических суставах и позвоночнике. Наблюдалась значимая корреляция данных магнитно-резонансной томографии и концентрации уровня С-реактивного белка в крови.

Об авторе

А. В. Смирнов



Литература

1. <div><p>Emery P., Fleischmann R.M., Moreland L.W. et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthr Rheum 2009;60:2272-83.</p><p>Keystone E.C., Genovese M.C., Klareskog L. et al. Golimumab, a human antibody to tumour necrosis factor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.</p><p>Smolen J.S., Kay J., Doyle M.K. et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomised, doubleblind, placebo-controlled, phase III trial. Lancet 2009;374:210-21.</p><p>Giovagnoni A., Valeri G., Burroni E., Amici F. Rheumatoid arthritis: follow-up and response to treatment. Eur J Radiol 1998;27(Suppl 1):25-30.</p><p>Peterfy C.G. New developments in imaging in rheumatoid arthritis. Curr Opin Rheum 2003;15:288-95.</p><p>McQueen F., Lassere M., Edmonds J. et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies: summary of OMERACT 6 MR imaging module. J Rheum 2003;30:1387-92.</p><p>Hoving J.L., Buchbinder R., Hall S. et al. A comparison of magnetic resonance imaging, sonography, and radiography of the hand in patients with early rheumatoid arthritis. J Rheum 2004;31:663-75.</p><p>Klarlund M., Ostergaard M., Jensen K.E. et al. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one-year follow up of patients with early arthritis. Ann Rheum Dis 2000;59:521-8.</p><p>Ostergaard M., Hansen M., Stoltenberg M. et al. New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier. Arthr Rheum 2003;48:2128-31.</p><p>Conaghan P.G., O’Connor P., McGonagle D. et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthr Rheum 2003;48:64-71.</p><p>McQueen F., Benton N., Perry D. et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthr Rheum 2003;48:1814-27.</p><p>Haavardsholm E.A., Boyesen P., Ostergaard M. et al. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 2008;67:794-800.</p><p>Hetland M.L., Ejbjerg B., Horslev-Petersen K. et al., and the CIMESTRA Study Group. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis: results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009;68:384-90.</p><p>Hetland M.L., Stengaard-Pedersen K., Junker P. et al., and the CIMESTRA Study Group. Radiographic progression and remission rates in early rheumatoid arthritis — MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomized CIMESTRA trial. Ann Rheum Dis 2010;69:1789-95.</p><p>Hodgson R.J., O’Connor P., Moots R. MRI of rheumatoid arthritis image quantitation for the assessment of disease activity, progression and response to therapy. Rheumatology (Oxford) 2008;47:13-21.</p><p>Boyesen P., Haavardsholm E.A., Ostergaard M. et al. MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Ann Rheum Dis 2011;70:428-33.</p><p>Dalbeth N., Smith T., Gray S. et al. Cellular characterization of magnetic resonance imaging bone oedema in rheumatoid arthritis: implications for pathogenesis of erosive disease. Ann Rheum Dis 2009;68:279-82.</p><p>Ostergaard M., Peterfy C., Conaghan P. et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies: core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system [published erratum appears in J Rheum 2004;31:198]. J Rheum 2003;30:1385-6.</p><p>Smolen J.S., van der Heijde D.M., St.Clair E.W. et al., for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Predictors of joint damage in patients with early rheumatoid arthritis treated with highdose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthr Rheum 2006;54:702-10.</p><p>Keystone E., van der Heijde D., Mason D. Jr et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthr Rheum 2008;58:3319-29.</p><p>Combe B., Dougados M., Goupille P. et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthr Rheum 2001;44:1736-43.</p><p>Jansen L.M., van der Horst-Bruinsma I.E., van Schaardenburg D. et al. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:924-7.</p><p>Lipsky P.E., van der Heijde D.M., St Clair E.W. et al., for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.</p><p>Bathon J.M., Martin R.W., Fleischmann R.M. et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published errata appear in N Engl J Med 2001;344:240 and N Engl J Med 2001;344:76]. N Engl J Med 2000;343:1586-93.</p><p>St.Clair E.W., van der Heijde D.M., Smolen J.S. et al., for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthr Rheum 2004;50:3432-43.</p><p>Breedveld F.C., Weisman M.H., Kavanaugh A.F. et al., for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthr Rheum 2006;54:26-37.</p><p>Weinblatt M.E., Keystone E.C., Furst D.E. et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthr Rheum 2003;48:35-45.</p><p>Klareskog L., van der Heijde D., de Jager J.P. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: doubleblind randomized controlled trial. Lancet 2004;363:675-81.</p><p>Ejbjerg B.J., Vestergaard A., Jacobsen S. et al. The smallest detectable difference and sensitivity to change of magnetic resonance imaging and radiographic scoring of structural joint damage in rheumatoid arthritis finger, wrist and toe joints: a comparison of the OMERACT rheumatoid arthritis magnetic resonance imaging score applied to different joint combinations and the Sharp/van der Heijde radiographic score. Arthr Rheum 2005;52:2300-6.</p><p>Emery P., Fleischmann R., van der Heijde D. et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthr Rheum 2011;63:1200-10.</p><p>Rahman M.U., Buchanan J., Doyle M.K. et al. Changes in patient characteristics in antitumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis 2011;70:1631-40.</p><p>Feterfy C.G. New developments in imaging in rheumatoid arthritis. Curr Opin Rheum 2003;15:288-95.</p><p>Hoving J.L., Buchbinder R., Hall S. et al. A comparison of magnetic resonance imaging, sonography, and radiography of the hand in patients with early rheumatoid arthritis. J Rheum 2004;31:663-75.</p><p>Klarlund M., Ostergaard M., Jensen K.E. et al. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis. The TIRA Group. Ann Rheum Dis 2000;59:521-8.</p><p>Оstergaard M., Hansen M., Stoltenberg M. et al. New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier. Arthr Rheum 2003;48:2128-31.</p><p>Оstergaard M., Pedersen S.J., Dohn U.M. Imaging in rheumatoid arthritis — status and recent advances for magnetic resonance imaging, ultrasonography, computed tomography and conventional radiography. Best Pract Res Clin Rheum 2008;22:1019-44.</p><p>Mundwiler M.L., Maranian P., Brown D.H. et al. The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study. Arthr Res Ther 2009;11:94. Comment in Arthr Res Ther 2009;11:124.</p><p>Schett G. Bone marrow edema. Ann NY Acad Sci 2009;1154:35-40.</p><p>Sieper J., Braun J., Rudwaleit M. et al. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002;61(Suppl 3):8—18.</p><p>Braun J., Landewу R., Hermann K.G. et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthr Rheum 2006;54:1646-52.</p><p>Lambert R.G., Salonen D., Rahman P. et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthr Rheum 2007;56:4005-14.</p><p>Baraliakos X., Davis J., Tsuji W. et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthr Rheum 2005;52:1216-23.</p><p>Braun J., Baraliakos X., Golder W. et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful thera py with infliximab: evaluation of a new scoring system. Arthr Rheum 2003;48:1126-36.</p><p>Sieper J., Baraliakos X., Listing J. et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 5 years of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 2005;44:1525-30.</p><p>Inman R.D., Davis J.C. Jr/, van der Heijde D. et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, doubleblind, placebo-controlled, phase III trial. Arthr Rheum 2008;58:3402-12.</p><p>Braun J., Deodhar A., Inman R. et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. Published Online First: 19 October 2011. doi:10.1136/ard.2011.154799.</p><p>Baraliakos X., Brandt J., Listing J. et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthr Rheum 2005;53:856-63.</p><p>Garrett S., Jenkinson T., Kennedy L.G. et al. A new approach to defining disease sta tus in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheum 1994;21:2286-91.</p><p>Van der Heijde D., Kavanaugh A., Gladman D.D. et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the Induction and Maintenance Psoriatic Arthritis Clinical Trial Arthr Rheum 2007;56:2698-707.</p><p>Mease P.J., Kivitz A.J., Burch F.X. et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthr Rheum 2004;50:2264-72.</p><p>Mease P.J., Gladman D.D., Ritchlin C.T. et al., for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthr Rheum 2005;52:3279-89.</p><p>Kavanaugh A. Year Safety, Efficacy, and Radiographic Data in Patients with Active Psoriatic Arthritis Treated with Golimumab: Results From the Long-Term Extension of a Randomized, Placebo-Controlled Study. ACR 2012 Abstr 2218.</p></div><br />


Для цитирования:


Смирнов А.В. Показатели рентгенологического прогрессирования и выраженности воспаления по результатам магнитно-резонансной томографии у больных ревматоидным артритом, анкилозирующим спондилитом и псориатическим артритом под влиянием терапии голимумабом. Современная ревматология. 2013;7(2):75-82. https://doi.org/10.14412/1996-7012-2013-2387

For citation:


Smirnov A.V. Golimumab therapy-induced indicators of X-ray inflammation progression and magnitude according to magnetic resonance imaging evidence in patients with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis. Modern Rheumatology Journal. 2013;7(2):75-82. (In Russ.) https://doi.org/10.14412/1996-7012-2013-2387

Просмотров: 745


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)